Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Health Care Utilization for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma: Experience from a Canadian Center

Victor H. Jimenez-Zepeda, Winson Y. Cheung, Mariet Mathew Stephen, Henry Chan

Blood (2024) 144 (Supplement 1): 7630.

https://doi.org/10.1182/blood-2024-203809

Published: 2024

Journal Articles

Clinical Outcomes for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma in Alberta, Canada

Victor H. Jimenez-Zepeda, Winson Y. Cheung, Mariet Mathew Stephen, Henry Chan

Blood (2024) 144 (Supplement 1): 6975.

https://doi.org/10.1182/blood-2024-205517

Published: 2024

Journal Articles

Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population

Victor H. Jimenez-Zepeda, Irwindeep Sandhu, Michael P. Chu, Kathryn Rankin, Arleigh McCurdy, Hyra Sapru, Christopher Cipkar, Edward Koo, Benjamin Patrick, Sarah Albert, Meriem Henia, Christopher McCudden, Alissa Visram

Blood (2024) 144 (Supplement 1): 1912.

https://doi.org/10.1182/blood-2024-209251

Published: 2024

Journal Articles

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, Engin Gul, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez-Zepeda, Kevin Song, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Martha L Louzada, Richard LeBlanc

Blood (2023) 142 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2023-181138

Published: 2023

Journal Articles

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Blood (2023) 142 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2023-174338

Published: 2023

Journal Articles

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10002–10004.

https://doi.org/10.1182/blood-2022-163661

Published: 2022

Journal Articles

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 289–291.

https://doi.org/10.1182/blood-2022-158219

Published: 2022

Journal Articles

The Canadian Registry for Amyloidosis Research: A National Multi-Disciplinary Registry for Real-World Evidence

Christopher P. Venner, Donna E. Reece, Steven Baker, Vera Bril, Diego Delgado, Mervyn Carr, Geneviève Giraldeau, Victoria Hodgkinson, Victor H Jimenez-Zepeda, Liam A. Laidlaw, Rami Massie, Marsha McWhinnie, Ian Paterson, Nowell Fine, Margot Davis

Blood (2022) 140 (Supplement 1): 13162–13163.

https://doi.org/10.1182/blood-2022-170086

Published: 2022

Journal Articles

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 4287–4289.

https://doi.org/10.1182/blood-2022-168843

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Richard Leblanc, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Michael P. Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha L Louzada, Hira S Mian, Darrell J White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7192–7194.

https://doi.org/10.1182/blood-2022-158679

Published: 2022

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Hira S Mian, Richard Leblanc, Martha L Louzada, Esther Masih-Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Michael Sebag, Darrell J White, Muhammad Aslam, Kevin W Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna E. Reece

Blood (2021) 138 (Supplement 1): 4721.

https://doi.org/10.1182/blood-2021-148191

Published: 2021

Journal Articles

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Christopher P. Venner, MD, Nizar J Bahlis, MD, Paola Neri, MD PhD, Irwindeep Sandhu, MD, Peter Duggan, MD, Andrew Belch, MD, Joanne D Hewitt, RN, BSN, NP, Linda M. Pilarski, PhD, Tatiana Nikitina, Victor H Jimenez-Zepeda, MD

Blood (2015) 126 (23): 4261.

https://doi.org/10.1182/blood.V126.23.4261.4261

Published: 2015

Journal Articles

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Marcia Culham, RN, BSN, NP, Joanne Luider, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 3189.

https://doi.org/10.1182/blood.V126.23.3189.3189

Published: 2015

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Victor H Jimenez-Zepeda, MD, Christopher P. Venner, MD, Andrew Belch, Irwindeep Sandhu, MD, Tatiana Nikitina, Joanne D Hewitt, RN, BSN, NP, Peter Duggan, MD, Paola Neri, MD PhD, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1845.

https://doi.org/10.1182/blood.V126.23.1845.1845

Published: 2015

Journal Articles

Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1846.

https://doi.org/10.1182/blood.V126.23.1846.1846

Published: 2015

Journal Articles

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Joanne Luider, Nizar J Bahlis, MD

Blood (2015) 126 (23): 5492.

https://doi.org/10.1182/blood.V126.23.5492.5492

Published: 2015

Journal Articles

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 5384.

https://doi.org/10.1182/blood.V126.23.5384.5384

Published: 2015

Journal Articles

Bortezomib Containing Regimens Are Highly Effective for Systemic AL Amyloidosis: Experience from a Single Center

Victor H Jimenez Zepeda, MD, Peter Duggan, MD, Paola E. Neri, MD PhD, Nizar J Bahlis, MD

Blood (2014) 124 (21): 4743.

https://doi.org/10.1182/blood.V124.21.4743.4743

Published: 2014

Journal Articles

Pomalidomide and Dexamethasone Is an Effective Regimen for Advanced-Stage Relapsed/Refractory Multiple Myeloma: Experience of a Single Center

Victor H Jimenez Zepeda, MD, Peter Duggan, MD, Paola E. Neri, MD PhD, Nizar J Bahlis, MD

Blood (2014) 124 (21): 5747.

https://doi.org/10.1182/blood.V124.21.5747.5747

Published: 2014

NARROW

Health Care Utilization for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma: Experience from a Canadian Center

Clinical Outcomes for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma in Alberta, Canada

Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

The Canadian Registry for Amyloidosis Research: A National Multi-Disciplinary Registry for Real-World Evidence

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Bortezomib Containing Regimens Are Highly Effective for Systemic AL Amyloidosis: Experience from a Single Center

Pomalidomide and Dexamethasone Is an Effective Regimen for Advanced-Stage Relapsed/Refractory Multiple Myeloma: Experience of a Single Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only